Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II

To overcome poor pharmacokinetics and toxicity of triptolide (TPL), a natural compound that exhibits potent anticancer activities, we developed a novel antibody-drug conjugate (ADC) to specifically deliver TPL to epidermal growth factor receptor (EGFR)-overexpressing non-small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Keqiang, Ma, Yuelong, Guo, Yuming, Sun, Ting, Wu, Jun, Pangeni, Rajendra P., Lin, Min, Li, Wendong, Horne, David, Raz, Dan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394741/
https://www.ncbi.nlm.nih.gov/pubmed/32775615
http://dx.doi.org/10.1016/j.omto.2020.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394741/
https://www.ncbi.nlm.nih.gov/pubmed/32775615
http://dx.doi.org/10.1016/j.omto.2020.07.001

Ejemplares similares